Kestra Medical Technologies (KMTS) CBO sells 15,256 shares for tax withholding

Rhea-AI Filing Summary

Kestra Medical Technologies Chief Business Officer Timothy P. Moran reported nondiscretionary sales of 15,256 common shares to cover tax withholding arising from vested restricted stock units. The shares were sold on July 30, July 31 and August 3, 2026 at weighted average prices of $22.7735, $22.6054 and $23.7611 per share within intraday ranges from $22.15 to $23.98.

Insider Trade Summary

Net Seller: 15,256 shares

Net Sell 3 txns

Insider Moran Timothy P.

Role Chief Business Officer

Sold 15,256 shs ($348K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F4	2,380	$23.7611	$57K
Sale	Common Shares F1, F3	8,759	$22.6054	$198K
Sale	Common Shares F1, F2	4,117	$22.7735	$94K

Holdings After Transaction: Common Shares — 66,345 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.3800 to $23.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1500 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.5800 to $23.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold 2026-08-03: 2,380 Common Shares Price 2026-08-03: $23.7611 per share Shares sold 2026-07-31: 8,759 Common Shares +4 more

7 metrics

Shares sold 2026-08-03 2,380 Common Shares Non-discretionary sell-to-cover sale on 2026-08-03

Price 2026-08-03 $23.7611 per share Weighted average sale price with range $23.5800-$23.9800

Shares sold 2026-07-31 8,759 Common Shares Non-discretionary sell-to-cover sale on 2026-07-31

Price 2026-07-31 $22.6054 per share Weighted average sale price with range $22.1500-$22.9200

Shares sold 2026-07-30 4,117 Common Shares Non-discretionary sell-to-cover sale on 2026-07-30

Price 2026-07-30 $22.7735 per share Weighted average sale price with range $22.3800-$23.0400

Total shares sold 15,256 Common Shares Aggregate of three sell-to-cover transactions reported

Key Terms

restricted stock units, sell to cover, weighted average price, tax withholding obligations

4 terms

restricted stock units financial

"vesting and settlement of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"pursuant to sell to cover transactions to satisfy tax"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"to satisfy tax withholding obligations in connection with the vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 07:35 PM Accepted by SEC EDGAR 08/03/2026 - 07:35 PM Learn about SEC filing dates

FAQ

What insider share sales did Kestra Medical Technologies (KMTS) report in this filing?

Chief Business Officer Timothy P. Moran reported selling 15,256 common shares of Kestra Medical Technologies. The transactions occurred over three days in late July and early August 2026 and were tied to tax withholding from vesting restricted stock units.

Were the KMTS insider sales by Timothy P. Moran discretionary or related to tax withholding?

The reported KMTS sales were nondiscretionary sell-to-cover transactions for tax withholding. Footnotes explain the shares were required to be sold to satisfy tax obligations from the vesting and settlement of restricted stock units.

On which dates did Timothy P. Moran sell KMTS shares and in what amounts?

Timothy P. Moran sold 4,117 shares on July 30, 8,759 shares on July 31, and 2,380 shares on August 3, 2026. All sales involved Kestra Medical common shares held directly and were linked to RSU tax withholding.

What prices were received in Timothy P. Moran’s KMTS share sales?

The weighted average sale prices were $22.7735 on July 30, $22.6054 on July 31, and $23.7611 on August 3, 2026. Footnotes state actual trade prices ranged from $22.15 to $23.98 per share across the three days.

Were Timothy P. Moran’s KMTS sales executed under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox was not selected in this filing. Instead, footnotes describe the transactions as nondiscretionary sell-to-cover sales required to satisfy tax withholding obligations from vesting restricted stock units.

What position does Timothy P. Moran hold at Kestra Medical Technologies (KMTS)?

Timothy P. Moran is identified as Kestra Medical Technologies’ Chief Business Officer. The Form 4 reports his direct ownership transactions in the company’s common shares related to tax withholding from restricted stock unit vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Timothy P.

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE

SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/30/2026		S(1)		4,117	D	$22.7735(2)	77,484	D
Common Shares	07/31/2026		S(1)		8,759	D	$22.6054(3)	68,725	D
Common Shares	08/03/2026		S(1)		2,380	D	$23.7611(4)	66,345	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.3800 to $23.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1500 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.5800 to $23.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

	/s/ Traci S. Umberger as attorney-in-fact for Timothy P. Moran	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)